Clinical Trial Update: Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy [Phase 1]

View source ↗

Summary

A completed Phase 1 trial evaluating neo-adjuvant combination immunotherapy in urothelial carcinoma of the bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Urothelial Carcinoma | Phase 1 | Status: COMPLETED